NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$13.42
-0.70 (-4.96%)
Close of Nov 06, 2026 · end-of-day data
IART 8-K filings in 2024
Every material Form 8-K Integra Lifesciences filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Integra LifeSciences adopted a change in control severance program on December 12, 2024, covering four executive officers and CFO Lea Knight. The program takes effect January 1, 2025, and pays severance only after a qualifying termination within two years of a change in control that occurs by December 31, 2025.
Program effective January 1, 2025, renewing a program that was scheduled to expire December 31, 2024
Lump sum severance of 1.5 times salary and target bonus, or 2 times for CFO Lea Knight
Includes COBRA premium support for up to 18 months and outplacement services for up to 12 months
Payments are conditioned on a general release of claims and may be reduced under a best pay cap for excise tax purposes
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Integra Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →